Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2008 / Cilt: 34 - Sayı: 2

Efficacy of carbohydrate antigens (CA 19-9, CA 125, CA 15-3) for diagnosis and prognostic factors of bladder tumor

Karbohidrat antijenlerinin (CA 19-9, CA 125, CA15-3)mesane tümörü tanısı ve hastalık seyrini belirlemedeki etkinliği

Pages
155–160
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Nevertheless, larger series are required for re-determining of the limit values, for urothelial tumors, cited in the literature

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: CA (Carbohydrate Antigen) 19-9, CA125, and CA15-3 are well known tumor markers that commonly used in gastrointestinal, ovarian epithelial malignity and breast cancers, respectively.
📊
Key Findings & Data:Particularly CA19-9 and CA125 levels are cited from time to time, and their prognostic importance are stressed more frequently.
💡
Conclusion & Impact:Nevertheless, larger series are required for re-determining of the limit values, for urothelial tumors, cited in the literature
🔬Design:Research Article
📍Scope:2001 Verileri
⚙️Variables:Tümör belirteci · biyolojik · Antijenler

Abstract

Introduction: CA (Carbohydrate Antigen) 19-9, CA125, and CA15-3 are well known tumor markers that commonly used in gastrointestinal, ovarian epithelial malignity and breast cancers, respectively. Particularly CA19-9 and CA125 levels are cited from time to time, and their prognostic importance are stressed more frequently. In our study, we compared serum CA19-9, CA125, and CA15-3 levels of our patients, those we follow with the diagnosis of bladder tumor, according to the features of the disease prospectively. Materials and Methods: Between March 2001 and June 2005, 61 patients that various therapies had been administered because of bladder tumor were included in the study, and 25 patients with benign prostate hyperplasia (BPH) complaining from hematuria initially selected as the control group. The patients with non- Transitional cell carcinoma bladder tumor (4/61) and with hematüria accompanying urinary infections or haemathologic problems (5/25) were excluded. Patients with bladder tumor were divided into two groups, as superficial and invasive groups. Each of the groups were compared individually and with controls in terms of CA19-9 (limit value; 37 IU/ml), CA125 (limit value; 35 IU/ml) and CA15-3 (limit value; 31 IU/ml). Stage, grade and number of focuses were evaluated as prognostic criterias. Independent t-test was used for statistical assessment. p<0.05 values were accepted as significant. Results: Transitional Cell Carcinoma (TCC) was present in 57 (74%) out of 77 patients who were included in the study. 21 (36.9%) of these were in the invasive group, and 36 (62.1%) were in the superficial group. Transurethral prostate resection was applied to 20 (26%) patients in the control group. Average ages of the tumor group and control group were 62.38±10.83 and 64.35±6.27, respectively and there were no statistically significant differences between these groups. When CA19-9, CA125 and CA15-3 levels of the tumor and control groups were compared, statistically significant differences were found in CA19-9 and CA15-3 levels. When comparison was performed in terms of prognostic factors, differences were observed in CA19-9 levels with regard to, size and grade of the tumor (p<0.05). There were no positive values detected for all the tumor markers in the control group. It was observed that CA19-9 was positive in 9 patients (15.7%), CA15-3 in 3 (5.7%), and CA125 in only 1 patient. Conclusion: We believe that carbohydrate antigens have limited efficiency and reliability in diagnosis and follow-up of bladder tumors and CA125 particularly has no place in the diagnosis of bladder tumor. In our study, finding positive results in some bladder tumor cases, suggests that CA19-9 and CA15-3 may have a diagnostic value and can be the indicators that demonstrate the presence of the tumor. Nevertheless, larger series are required for re-determining of the limit values, for urothelial tumors, cited in the literature

Özet

Çalışmamızda mesane Değişici Hücreli Kanseri (DHK) nedeniyle izlediğimiz hastaların serum CA19-9, CA125 ve CA15-3 düzeylerini hastalık özelliklerine göre prospektif olarak karşılaştırdık. Mesane tümörü nedeniyle çeşitli tedaviler uygulanan 61 hasta ile hematüri şikayeti ile başvuran Benin Prostat Hiperplazili (BPH) 25 hasta kontrol grubu olarak çalışmaya alındı. DHK dışı mesane tümörü olan hastalar (4/61) ve hematüriye eşlik eden üriner enfeksiyon veya hematolojik problemleri olan hastalar (5/25) çalışma dışı bırakıldı. Mesane tümörlü hastalar yüzeyel ve derin olmak üzere iki gruba ayrıldı. Her iki grup kendi arasında ve tümörlü olan ve olmayan hasta grupları ayrı ayrı CA19-9, CA125 ve CA15-3 düzeyleri açısından karşılaştırıldı. DHK’li hastaların 21 tanesi (%36,9) invaziv, 36 tanesi (%63,1) yüzeyel grupta bulunuyordu. Tümör grubuyla kontrol grubunun CA19-9, CA125, CA15-3 düzeyleri karşılaştırıldığında istatistiksel olarak farklılık CA19-9 ve CA15-3 arasında bulundu. Prognostik etkenler açısından değerlendirildiğinde, evre, farklılaşma derecesi ve tümör boyutu açısından CA19-9 düzeylerinde farklılık saptandı (p<0,05). Tümör belirleyicileri yönünden kontrol grubunda pozitif değer yoktu. Mesane tümörlü hastalarda CA19-9’un 9 (%15,7), CA15-3’ün 3 (%5,2) ve CA125’in sadece 1 hastada pozitif olduğu gözlendi.

🔖

Cite This Article

KOŞAN, M., TÜL, M., GÖNÜLALAN, U., UĞURLU, Ö., İNAL, G., ADSAN, Ö. (2008). Efficacy of carbohydrate antigens (CA 19-9, CA 125, CA 15-3) for diagnosis and prognostic factors of bladder tumor. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 34 - Sayı: 2, 155–160. https://ajindex.com/articles/328241

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Tinzl M, Marberger M: Urinary markers for detecting bladder cancer. EAU Update Series vol. 1: 64-70, 2003
  2. Koprowski H, Steplewski Z, Mitchell K, et al: Colorec- tal carcinoma antigen detected by hybridoma antibodies. Somat Cell Genet. 5:957-972, 1979
  3. Bast RC Jr, Klug TL, St John TL, et al: A radioimmu- noassay using a monoclonal antibody to monitor the co- urse of epithelial ovarian cancer. N Engl J Med. 13; 309: 883-887, 1983
  4. Hayes DF: Tumor markers for breast cancer. Ann Oncol. 4: 807-819, 1993
  5. Abel PD, Cornell C, Buamah PK, et al: Assessment of serum CA 19.9 as a tumor marker in patients with carci- noma of the bladder and prostate. BJU. 59: 427-429, 1987
  6. Guarnaccia S, Pais V, Grous J, et al: Adenocarcinoma of the urachus associated with elevated levels of CA 125. J Urol. 145: 140-141, 1991
  7. Fleming ID, Cooper JS, Henson DE et al: AJCC Can- cer Staging Manual, 5th ed. Philadelphia: Lippincott-Ra- ven, 241, 1997
  8. Epstein JI, Amin MB, Reuter VR, et al: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transiti- onal cell) neoplasms of the urinary bladder. Bladder Con- sensus Conference Committee. Am J Surg Pathol. 22: 1435-1448, 1998
  9. Pectasides D, Bafaloucos D, Antoniou F, et al: TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol. 19: 271-277, 1996
  10. Giannopoulos A, Manousakas T, Mitropoulos D, et al: Comparative evaluation of the BTAstat test, NMP22 and voided urine cytology in the detection of primary and re- current bladder tumors. Urology. 55: 871-875, 2000
  11. Lange PH, Limas C, Fraley EE: Tissue blood-group antigens and prognosis in low stage transitional cell car- cinoma of the bladder. J Urol. 119: 52-55, 1978
  12. Coon JS, McCall A, Miller AW 3rd, et al: Expression of blood-group-related antigens in carcinoma in situ of the urinary bladder. Cancer 56: 797-804, 1985
  13. Takada A, Ohmori K, Yoneda T, Tsuyuoka K, et al: Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vas- cular endothelium. Cancer Res. 53: 354-361, 1993
  14. Varki A: Selectin ligands. Proc Natl Acad Sci USA 91: 7390-7397, 1994
  15. Saito K, Fujii Y, Kawakami S, et al: Increased expres- sion of sialyl-Lewis A correlates with poor survival in upper urinary tract urothelial cancer patients. Anticancer Res. 23: 3441-3446, 2003
  16. Kikuno N, Urakami